MedKoo Cat#: 535249 | Name: EPI-7170

Description:

WARNING: This product is for research use only, not for human or veterinary use.

EPI-7170 is a potent androgen receptor N-terminal domain antagonist, decreasing expression of DNA repair genes, sensitizing prostate cancer cells that express full-length AR and AR-Vs to radiotherapy.

Chemical Structure

EPI-7170
EPI-7170
CAS#2139288-26-7

Theoretical Analysis

MedKoo Cat#: 535249

Name: EPI-7170

CAS#: 2139288-26-7

Chemical Formula: C22H28Cl3NO6S

Exact Mass: 539.0703

Molecular Weight: 540.88

Elemental Analysis: C, 48.85; H, 5.22; Cl, 19.66; N, 2.59; O, 17.75; S, 5.93

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
2139288-26-7 2139289-01-1 (racemic)
Synonym
EPI-7170; EPI 7170; EPI7170
IUPAC/Chemical Name
N-((R)-3-(4-(2-(3,5-Dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)-2-hydroxypropyl)methanesulfonamide
InChi Key
DCXVYXPVNSMWPG-IAGOWNOFSA-N
InChi Code
InChI=1S/C22H28Cl3NO6S/c1-22(2,15-8-19(24)21(20(25)9-15)32-12-16(27)10-23)14-4-6-18(7-5-14)31-13-17(28)11-26-33(3,29)30/h4-9,16-17,26-28H,10-13H2,1-3H3/t16-,17-/m1/s1
SMILES Code
CS(=O)(NC[C@@H](O)COC1=CC=C(C(C)(C2=CC(Cl)=C(OC[C@H](O)CCl)C(Cl)=C2)C)C=C1)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 540.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Hirayama Y, Tam T, Jian K, Andersen RJ, Sadar MD. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer. Mol Oncol. 2020 Jul 30. doi: 10.1002/1878-0261.12770. Epub ahead of print. PMID: 32734688. 2: Banuelos CA, Ito Y, Obst JK, Mawji NR, Wang J, Hirayama Y, Leung JK, Tam T, Tien AH, Andersen RJ, Sadar MD. Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants. Cancers (Basel). 2020 Jul 21;12(7):E1991. doi: 10.3390/cancers12071991. PMID: 32708219.